August, 2013
Posted by Tim Mushen on
Nortis is awarded funding by the PATH Malaria Vaccine Initiative (MVI) to develop a platform for testing transmission blocking vaccines.
← Older Post Newer Post →
Posted by Tim Mushen on
← Older Post Newer Post →